Showing results (81-90 of 108) with videos related to
Sort By:
Pageof 11
Tumori|July 7, 2023
Outcomes in patients with <i>BRAF</i><sup>V600</sup>-mutated melanoma and brain metastases at baseline treated with dabrafenib plus trametinibMassimo Aglietta, Vanna Chiarion-Sileni, Paolo Fava, et al.Targeted Oncology|November 10, 2021
Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy)Massimo Aglietta, Vanna Chiarion-Sileni, Paolo Fava, et al.Frontiers in Oncology|September 1, 2022
Comparison Between First Line Target Therapy and Immunotherapy in Different Prognostic Categories of BRAF Mutant Metastatic Melanoma Patients: An Italian Melanoma Intergroup StudyRiccardo Marconcini, Paolo Fava, Amedeo Nuzzo, et al.Cancers|February 3, 2021
No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) StudyMichele Guida, Nicola Bartolomeo, Pietro Quaglino, et al.Cancer Immunology, Immunotherapy : CII|August 28, 2023
Systematic vitamin D supplementation is associated with improved outcomes and reduced thyroid adverse events in patients with cancer treated with immune checkpoint inhibitors: results from the prospective PROVIDENCE studyMelissa Bersanelli, Alessio Cortellini, Alessandro Leonetti, et al.Journal for Immunotherapy of Cancer|November 16, 2019
The density and spatial tissue distribution of CD8<sup>+</sup> and CD163<sup>+</sup> immune cells predict response and outcome in melanoma patients receiving MAPK inhibitorsDaniela Massi, Eliana Rulli, Mara Cossa, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2022
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated <i>BRAF</i>-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II TrialPaolo A Ascierto, Mario Mandalà, Pier Francesso Ferrucci, et al.European Journal of Cancer (Oxford, England : 1990)|January 24, 2024
Combined immunotherapy in melanoma patients with brain metastases: A multicenter international studyMario Mandalà, Paul Lorigan, Maria Chiara Sergi, et al.Frontiers in Oncology|October 12, 2020
An Italian Retrospective Survey on Bone Metastasis in Melanoma: Impact of Immunotherapy and Radiotherapy on SurvivalFrancesco Mannavola, Mario Mandala, Annalisa Todisco, et al.European Journal of Cancer (Oxford, England : 1990)|June 12, 2025
Combined immunotherapy with nivolumab and ipilimumab with and without sequential or concomitant stereotactic radiotherapy in patients with melanoma brain metastasis: An international retrospective studyMario Mandalà, Teresa Amaral, Piotr Rutkowski, et al.Pageof 11